Amicus Therapeutics, Inc.

FOLD

$14.43

Name : Amicus Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $4,531,030,016.00

EPSttm : -0.09

Amicus Therapeutics, Inc.

$14.43

0.14%

$0.02

FOLD — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

6.53

Margin Of Safety %

-19

Put/Call OI Ratio

0.66

EPS Next Q Diff

0.14

EPS Last/This Y

0.74

EPS This/Next Y

0.27

Price

14.41

Target Price

14.5

Analyst Recom

Performance Q

1.12

Upside

-121.9%

Beta

0.48

Ticker: FOLD

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	FOLD	14.36	0.69	9.79	16371
2026-03-03	FOLD	14.35	0.76	0.37	17196
2026-03-04	FOLD	14.34	0.76	0.00	17232
2026-03-05	FOLD	14.34	0.73	1.42	17643
2026-03-06	FOLD	14.34	0.73	0.50	17686
2026-03-09	FOLD	14.36	0.73	1.48	17656
2026-03-10	FOLD	14.35	0.73	62.20	17762
2026-03-11	FOLD	14.38	0.70	0.00	17456
2026-03-12	FOLD	14.37	0.70	0.00	17488
2026-03-13	FOLD	14.37	0.70	0.00	17488
2026-03-17	FOLD	14.37	0.69	999.99	17623
2026-03-18	FOLD	14.38	0.69	0.00	17627
2026-03-19	FOLD	14.38	0.69	999.99	17670
2026-03-20	FOLD	14.4	0.69	0.00	17681
2026-03-23	FOLD	14.41	0.65	1.02	16986
2026-03-24	FOLD	14.41	0.66	1.43	17052
2026-03-25	FOLD	14.43	0.67	0.47	17216
2026-03-26	FOLD	14.43	0.67	0.00	17298
2026-03-27	FOLD	14.41	0.66	0.67	17348
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	FOLD	14.37	210.1	318.1	0.65
2026-03-03	FOLD	14.35	210.1	165.1	0.65
2026-03-04	FOLD	14.34	210.1	164.9	0.65
2026-03-05	FOLD	14.33	210.1	164.9	0.65
2026-03-06	FOLD	14.34	210.1	165.0	0.65
2026-03-09	FOLD	14.36	210.1	165.3	0.65
2026-03-10	FOLD	14.36	210.1	165.2	0.65
2026-03-11	FOLD	14.38	210.1	165.5	0.65
2026-03-12	FOLD	14.37	210.1	165.5	0.65
2026-03-13	FOLD	14.38	210.1	165.5	0.65
2026-03-17	FOLD	14.37	210.1	165.6	0.65
2026-03-18	FOLD	14.37	210.1	165.5	0.65
2026-03-19	FOLD	14.38	210.1	165.4	0.65
2026-03-20	FOLD	14.41	210.1	166.0	0.65
2026-03-23	FOLD	14.41	210.1	166.1	0.65
2026-03-24	FOLD	14.41	210.1	166.0	0.65
2026-03-25	FOLD	14.42	210.1	166.1	0.65
2026-03-26	FOLD	14.43	210.1	166.2	0.65
2026-03-27	FOLD	14.41	210.1	166.1	0.65
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	FOLD	-8.89	2.40	5.70
2026-03-03	FOLD	-8.89	2.40	5.70
2026-03-04	FOLD	-8.89	2.40	5.70
2026-03-05	FOLD	-9.29	2.40	5.70
2026-03-06	FOLD	-9.29	2.40	5.70
2026-03-09	FOLD	-9.29	2.43	5.70
2026-03-10	FOLD	-9.29	2.43	5.70
2026-03-11	FOLD	-9.29	2.43	6.14
2026-03-12	FOLD	-9.29	2.43	6.14
2026-03-13	FOLD	-9.29	2.43	6.14
2026-03-17	FOLD	-9.29	2.43	6.14
2026-03-18	FOLD	-9.29	2.43	6.14
2026-03-19	FOLD	-9.29	2.43	6.14
2026-03-20	FOLD	-9.29	2.43	6.14
2026-03-23	FOLD	-9.29	2.43	6.14
2026-03-24	FOLD	-9.29	2.43	6.14
2026-03-25	FOLD	-9.29	2.43	6.53
2026-03-26	FOLD	-9.29	2.43	6.53
2026-03-27	FOLD	-9.29	2.43	6.53
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.01

Avg. EPS Est. Current Quarter

0.09

Avg. EPS Est. Next Quarter

0.15

Insider Transactions

-9.29

Institutional Transactions

2.43

Beta

0.48

Average Sales Estimate Current Quarter

165

Average Sales Estimate Next Quarter

182

Fair Value

11.73

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.1

Max Drawdown 5-Year %

-61.2

Target Price

14.5

P/E

Forward P/E

23.86

PEG

P/S

7.13

P/B

16.33

P/Free Cash Flow

151.58

EPS

-0.09

Average EPS Est. Cur. Y

0.65

EPS Next Y. (Est.)

0.92

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-4.27

Relative Volume

0.34

Return on Equity vs Sector %

-37.2

Return on Equity vs Industry %

-21

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

166.1

◆ FOLD Healthcare

$14.41

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

0/20

Pullback

0/25

Volume

11/15

Valuation

6/20

TP/AR

0/10

Options

7/10

RSI

66.4

Range 1M

86.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

17/30

Estimates

4/20

Inst/Vol

6/15

Options

5/10

EPS Yr

436.5%

EPS NY

99.4%

52W%

99.8%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +56.3% upside

Quality

6/30

Valuation

14/30

Growth

14/25

Stability

5/10

LT Trend

1/5

Upside

+56.3%

Quality

MoS

-19%

Amicus Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 511

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

FOLD

Latest News

—

Caricamento notizie per FOLD…

stock quote shares FOLD – Amicus Therapeutics, Inc. Stock Price stock today

news today FOLD – Amicus Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch FOLD – Amicus Therapeutics, Inc. yahoo finance google finance

stock history FOLD – Amicus Therapeutics, Inc. invest stock market

stock prices FOLD premarket after hours

ticker FOLD fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: FOLD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y